
Shorla Oncology Announces Expansion of U.S. Commercial Footprint with Launch of Dedicated Sales Force and Market Access Teams
Company to Roll Out Availability of IMKELDI (imatinib) for Patients with Certain Forms of Leukemia and Other Cancers CAMBRIDGE, Mass. March 4, 2025 – Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced the launch of a dedicated sales force and market access teams and the commercial availability of IMKELDI, the first oral liquid […]